News

Nasoni Takes the Lead in Transforming Care for Alzheimer’s and Dementia Patients with $2.4M Federal Grant

Hampton Roads stands at the forefront of innovation by announcing a $2.4 million federal grant to enhance care for Alzheimer’s and dementia patients. This funding, spearheaded by Congresswoman Jen Kiggans, not only highlights the region’s commitment to healthcare but also emphasizes the role of local startups like Nasoni, which are driving the future of patient care.

Nasoni, a forward-thinking Hampton Roads startup known for its innovative faucet designs, is expanding its reach into healthcare with solutions that improve the quality of life for patients facing cognitive challenges. As part of the broader effort supported by the federal grant, Nasoni will play a crucial role in developing practical, user-friendly technologies to assist patients and caregivers alike.

Their patented faucets, designed with ease of use in mind, are particularly valuable for individuals with Alzheimer’s and dementia. With simple features that allow for better access to clean water, Nasoni’s faucets reduce daily stress and improve hydration—an often overlooked but critical aspect of care for aging populations.

Founder Steve Waddell is optimistic about Nasoni’s impact. “Our goal has always been to make life easier through innovative design,” Waddell says. With this grant, we can extend that mission to vulnerable populations in Hampton Roads, providing practical solutions that ease the burdens of care.”

Kiggans, a former geriatric nurse practitioner, recognizes the importance of such local innovations. “Companies like Nasoni are key to revolutionizing the way we support Alzheimer’s and dementia patients. Their commitment to improving everyday tasks like access to clean water aligns with our goal of enhancing patient care in meaningful ways,” she shared during the announcement.

In addition to Nasoni’s contributions, the grant will fund various community-based programs, caregiver training, and healthcare initiatives designed to enhance early detection and personalized care strategies. By combining Nasoni’s innovative products with these expanded services, Hampton Roads is set to become a model for Alzheimer’s and dementia care.

The collaboration between local businesses and healthcare providers underscores the region’s thriving ecosystem of startups and technology. As Nasoni continues to expand its influence, its work will serve as a shining example of how ingenuity can positively impact patient care on a large scale.

This grant not only advances the fight against Alzheimer’s and dementia but also highlights the role of Hampton Roads startups in solving critical healthcare challenges. With Nasoni’s help, the future of care in the region looks brighter than ever.

 

Read more here.

Recent News

11/21/2025

A new era of global growth: George Mason and Naugen launch international innovation accelerator

This month, a new Northern Virginia International Soft-Landing Accelerator (NISA) program, designed to help start-ups from around the globe find guidance, connections, and lab or office spaces at no cost, was launched to help develop new technologies in life sciences.Applications are now open for the first NISA cohort. Participants in the six-month program will have

11/20/2025

VIPC Signs MOU with AstraZeneca, Eli Lilly, Merck to Develop the Virginia Center for Advanced Pharmaceutical Manufacturing to Train Workforce of the Future

A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia’s life sciences ecosystem, higher-ed universities, and community colleges on October 31. This

11/11/2025

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Specifically, a rapamycin loading concentration of 4% w/w has been achieved for Quoin’s proprietary topical